ABSTRACT
INTRODUCTION
Pre-eclampsia is a leading cause of maternal mortality and morbidity that imposes a substantial burden on the healthcare system 1 . Significant efforts have been devoted to developing clinically useful screening methods and prevention strategies for pre-eclampsia. Although the recommended approach to screening for pre-eclampsia is blood pressure monitoring 2 , the ASPRE trial has shown that it is possible to predict the development of early-onset pre-eclampsia with good precision using a combination of maternal factors and biomarkers in the first trimester of pregnancy 3 . Early prediction is quite important as aspirin, the only proven preventative method for pre-eclampsia, has a dose-and time-dependent effect 4 . Early prediction and additional interventions could boost the beneficial effects of aspirin 5 . However, only 12% of all pre-eclampsia cases are early-onset and prediction models show poorer precision for late-onset disease 3, 6 . Furthermore, aspirin failed to show a clinically meaningful effect on the development of late-onset pre-eclampsia, in which the majority of the disease burden lies 7 . Therefore, a preventative method targeting both early-and late-onset pre-eclampsia is highly desirable.
Metformin is a biguanide that prevents gluconeogenesis in the liver and increases the sensitivity of the peripheral tissue to insulin. The use of metformin in obstetrics is gaining pace as it has been shown to be efficacious in the treatment of gestational diabetes mellitus (GDM) and possibly in the prevention of pre-eclampsia [8] [9] [10] . A plausible mechanism by which metformin, an anti-diabetic agent, might prevent pre-eclampsia is suggested in an in-vivo study by Brownfoot et al. 11 , which demonstrated that metformin reduces soluble fms-like tyrosine kinase-1 levels, which correlate significantly with gestational age at onset of pre-eclampsia and severity 12 . It has also been suggested that metformin may prevent pre-eclampsia by improving cardiovascular function and limiting gestational weight gain 13 . Regardless of the underlying mechanism, the clinical implications are very important if metformin is proven effective in preventing late-onset pre-eclampsia. However, a randomized trial investigating the effects of metformin on the development of pre-eclampsia as the primary outcome is yet to be conducted. The main aim of this systematic review and meta-analysis was to determine whether metformin prevents hypertensive disorders of pregnancy.
METHODS

Protocol, eligibility criteria, information sources and search
This review was performed according to a protocol designed a priori and recommended for systematic reviews and meta-analyses [14] [15] [16] [17] [18] . MEDLINE (1947 to September 2017), Scopus (1970 to September 2017) and the Cochrane Library (inception to September 2017), including The Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE) and The Cochrane Central Register of Controlled Trials (CENTRAL), were searched electronically in September 2017, utilizing combinations of the relevant MeSH terms, keywords and word variants for 'metformin', 'pregnancy', 'preeclampsia', 'hypertension', 'randomized' and 'gestational hypertension' (Appendix S1). The search was restricted to randomized trials in the English language. Reference lists of relevant articles and reviews were hand searched for additional reports. The PRISMA guidelines were followed 16 . The study was registered with the PROSPERO database (registration number CRD42017080369).
Study selection, data collection and data items
Studies were assessed according to the following criteria: population, outcome, type of hypertensive disorder, gestational weight gain and gestational age at initiation of metformin therapy. Only randomized controlled trials reporting the incidence of pre-eclampsia or pregnancy-induced hypertension were included. Studies in which metformin treatment was received prior to randomization were excluded. All abstracts were reviewed independently by two authors (E.K. and Y.E.S.). Agreement about potential relevance was reached by consensus, and full-text copies of those papers were obtained. The same two reviewers extracted data independently regarding the study characteristics and outcomes. Inconsistencies were discussed by the reviewers and consensus reached. If more than one study was published using the same cohort with identical endpoints, only the report containing the most comprehensive information on the population was included to avoid overlapping populations. Cohort studies, case-control studies, case series, case reports, conference abstracts and editorials were excluded. Studies were included in which data on pregnancy outcome, including incidence of pre-eclampsia and gestational hypertension, could be extracted.
Risk of bias, summary measures and synthesis of results
Risk of bias of the included studies was assessed using the Cochrane risk of bias tool 17 . Quality of evidence was assessed using the GRADE approach developed by the Grading of Recommendations, Assessment, Development and Evaluations Working Group. Data on the type of intervention, gestational age at randomization, gestational age at delivery and the incidence of hypertensive disorders, with corresponding participant numbers, were extracted from each included study. Analysis of the extracted data was performed using RStudio (Version 1.0.136, RStudio, Inc., Boston, MA, USA). For binary outcomes, a random-effects model with the Mantel-Haenszel method was used for pooling of studies. Relative risks (RR) were obtained for binary outcomes. The variance between studies was tested using the I 2 statistic. When the number of included studies was adequate, publication bias was explored using a funnel plot asymmetry test (i.e. Egger test) 19, 20 . Due to the low number of studies in each subgroup analysis, a Bayesian meta-regression or meta-analysis was employed to synthesize the evidence regarding metformin use and hypertensive disorders of pregnancy using the comparator (insulin, glyburide, placebo) as a covariate. A normal distribution (N∼0,10.000) for the mean effect estimates and a uniform distribution (U∼0,5) for the variance estimates were used as vague priors for Bayesian random-effects meta-regression. Posterior probabilities were calculated of an intervention having a protective effect against the hypertensive disorders of pregnancy. A fixed-effects method for Bayesian analysis was used when posterior density plots for heterogeneity showed minimal between-study variation (< 1 SD). Convergence diagnostics were made with Gelman-Rubin statistic and trace plots. All Bayesian computations were performed using Markov Chain Monte-Carlo (MCMC) sampler in R. MCMC sampling was run for each analysis for 3 000 000 iterations after discarding the first 50 000.
RESULTS
Study selection, characteristics and risk of bias
In total, 3337 citations matched the search criteria and three additional studies were identified via manual searching ( Figure 1 ). After removing duplicate and irrelevant studies, 52 were retrieved for full text review. Studies were excluded due to the reported outcome being not relevant (n = 15), study design not matching our protocol (n = 13) or overlapping populations (n = 4). Another study was excluded due to unacceptably high risk of bias 21 and four studies due to metformin use prior to randomization [22] [23] [24] [25] , leaving 15 studies to be included in the meta-analysis. The methodological characteristics of the included studies are shown in Table 1 . The participants' characteristics varied among the studies, which included women with GDM (13 studies) or obese women (two studies). Metformin was compared with insulin (eight studies), placebo (two studies) or glyburide (five studies) 10, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . Mean gestational age at randomization and the risk characteristics differed greatly among the studies (Table 1) . Planned metformin dose, received metformin dose, additional treatment and compliance also varied among the studies, contributing to the observed clinical heterogeneity (Table 2) . A summary of the qualitative evaluation of the included studies according to the Cochrane risk of bias tool is presented in Table 3 . All trials were considered to be at low risk of blinding bias due to the low probability of blinding affecting the occurrence of pre-eclampsia or pregnancy-induced hypertension.
Synthesis of results
Studies were grouped according to the comparator treatment and analyzed for different outcomes. Metformin use was associated with a reduced risk of pregnancy-induced hypertension when compared with insulin (RR, 0.56; 95% CI, 0.37-0.85; Table 4 ) in women with GDM. Although the risk estimate for pre-eclampsia (RR, 0.83; 95% CI, 0.60-1.14) was lower for metformin use when compared with insulin use, the difference did not reach statistical significance (Table 4 and Figure S1 ). According to Bayesian random-effects meta-analysis, in women with GDM, the posterior probabilities of metformin having a beneficial effect on the prevention of pre-eclampsia, pregnancy-induced hypertension and any HDP were 93.5%, 86.7% and 97.7%, respectively (Table 4) . In women with GDM, metformin use was associated with a non-significant reduction in pre-eclampsia (RR, 0.66; 95% CI, 0.11-3.82), pregnancy-induced hypertension (RR, 0.79; 95% CI, 0.42-1.49) and any HDP (RR, 0.71; 95% CI, 0.41-1.25) when compared with glyburide (Table 4 and Figure S2 ). According to Bayesian random-effects meta-analysis, in women with GDM, the posterior probabilities of metformin having a beneficial effect on the prevention of pre-eclampsia, pregnancy-induced hypertension and any HDP were 50.7%, 50.0% and 74.3%, respectively (Table 4) .
When compared with placebo, metformin use was associated with a non-significant reduction in pre-eclampsia in obese women (RR, 0.74; 95% CI, 0.09-6.28; Table 4 and Figure S3 ). The number of studies included in this analysis was small (n = 2) with high statistical heterogeneity (I 2 = 86%). According to Bayesian random-effects meta-analysis, in obese women, the posterior probabilities of metformin having a beneficial effect on the prevention of pre-eclampsia, pregnancy-induced hypertension and any HDP were 46.0%, 43.4% and 43.2%, respectively (Table 4) . Due to the low number of studies and methodological similarities between the studies, a fixed-effects model analysis was also performed. The risk of pre-eclampsia was lower for metformin use in the fixed-effects model (RR, 0.51; 95% CI, 0.26-0.98), with high statistical heterogeneity (I 2 = 86%). The posterior probability (fixed-effects Bayesian model) of a beneficial effect was 99.4% (odds ratio (OR), 0.54; 95% credible intervals (CrI), 0.25-0.95). No study compared metformin with placebo in women with GDM and none compared metformin with insulin in obese women, as expected.
When the available evidence was combined using a Bayesian random-effects meta-regression with treatment type as a covariate, the posterior probabilities of metformin having a beneficial effect on the prevention of pre-eclampsia, pregnancy-induced hypertension and any HDP were 92.7% (OR, 0.72; 95% CrI, 0.42-1.16), 92.8% (OR, 0.74; 95% CrI, 0.43-1.12) and 99.2% (OR, 0.71; 95% CrI, 0.50-0.98), respectively, when compared with other treatments (Figure 2 ). Between-study variance in these analyses was small (Figures 2 and S4) .
The overall quality of evidence was low or very low. Most analyses were downgraded one point for imprecision and at least one point for indirectness (Tables 4 and S1 ). Publication bias was not investigated formally due to the low number of studies in each subgroup analysis. 
⊕⊝⊝⊝
Very low *Random-effects meta-analysis using Mantel-Haenszel method. †Bayesian random-effects meta-analysis with vague priors (normal or t-distribution). ‡Bayesian fixed-effects meta-analysis with vague priors (normal or t-distribution). §Bayesian random-effects meta-regression using comparator treatment as a covariate. HDP, hypertensive disorder of pregnancy; NA, not applicable; ND, no data; PIH, pregnancyinduced hypertension; RR, relative risk.
DISCUSSION
Summary of main findings
In this meta-analysis of randomized trials, metformin, when compared with insulin, reduced the risk of pregnancy-induced hypertension in women with GDM. Furthermore, metformin use, when compared with other treatments and placebo, was associated with a high probability of prevention of any HPD. The analyses were characterized by a low number of included studies, significant clinical heterogeneity and low quality of evidence.
Study strengths and limitations
We included all randomized trials in which metformin was compared with any treatment modality or placebo. The total number of studies included in the quantitative analysis was modest (n = 15). Although we could not perform a subgroup analysis for early-and late-onset pre-eclampsia, metformin randomization was before 30 weeks' gestation in most of the included studies, indicating that the summary effect we observed is likely due to the prevention of late-onset pre-eclampsia. Another limitation of this analysis was the clinical heterogeneity among the included studies. It is important to note that diagnostic criteria for the outcome measures differed between studies but the diagnostic criteria of pre-eclampsia and pregnancy-induced hypertension are fairly similar among the available guidelines. Also, HDP was not the primary outcome measure in any of the included studies and metformin was not specifically tested for the prevention of HDP. This is an important confounder and the effect observed in these studies could be due to another uncontrolled factor (i.e. gestational weight gain). We used both random-and fixed-effects models for studies comparing metformin with placebo, which yielded conflicting results. The studies included in this analysis were quite similar in their design and execution, and thus were characterized by low clinical Moore (2010) 27 Nachum (2017) 26 Pujara (2017) 37 Silva (2010) 34 Ainuddin (2014) 28 Ijas (2011) 31 Najafian (2017) 38 Niromanesh (2012) 32 Rowan (2008) 33 Saleh (2016) 39 Spaulonci (2013) 35 Tertti (2013) 36 Chiswick (2015) 29 Syngelaki (2016) Silva (2010) 34 Ainuddin (2014) 28 Niromanesh (2012) 32 Rowan (2008) 33 Tertti (2013) 36 Chiswick (2015) 29 Syngelaki (2016) 10 Summary estimate Moore (2010) 27 Ainuddin (2014) 28 Ijas (2011) 31 Najafian (2017) 38 Niromanesh (2012) 32 Rowan (2008) 33 Saleh (2016) 39 Spaulonci (2013) 35 Tertti (2013) 36 Chiswick (2015) 29 Syngelaki (2016) heterogeneity but high statistical heterogeneity. However, it is unlikely that the summary estimates presented by either method are good representations of the real effect. The Bayesian random-effects meta-analysis was in agreement with this assessment, as the posterior estimates were dominated by the vague prior information (posterior probability ∼50%), indicating that the current evidence is too weak to draw firm conclusions for this subgroup. The majority of the evidence stemmed from studies comparing metformin with insulin in women with GDM. However, the magnitude of effect was relatively constant among other comparators but without statistical significance, which was probably due to an insufficient number of included studies. Also, our review comprises two main populations of pregnant women, i.e. women with GDM and obese women. The results obtained in the current study are mainly applicable to such populations. Women with a high probability of metformin use prior to randomization (those with type II diabetes or polycystic ovary syndrome) were excluded in this meta-analysis and the results we have obtained cannot be applied to these populations.
Comparison with existing literature and research implications
Although the use of metformin in pregnant women dates back to 1979, it has recently become a popular treatment choice for GDM due to its apparent effectiveness, safety in pregnancy, ease of use and high compliance rate 40 . The effectiveness of metformin compared with that of insulin in managing GDM was demonstrated in a meta-analysis by Gui et al. 41 . In a subgroup analysis, Gui et al. reported that the prevalence of pre-eclampsia was similar between the metformin and insulin groups (OR, 0.69; 95% CI, 0.42-1.12). However, this analysis included only three studies. Two previous meta-analyses by Feng et al. and Butalia et al . demonstrated a significant effect of metformin in reducing the incidence of pre-eclampsia in women with GDM (RR, 0.70 (95% CI, 0.49-0.99) and 0.56 (95% CI, 0.37-0.85), respectively) 9, 42 . Again, these were subgroup analyses within studies aimed at assessing the effect of metformin on the treatment of diabetes during pregnancy. Notably, these meta-analyses did not report pre-eclampsia and pregnancy-induced hypertension outcomes separately. A recent Cochrane review by Brown et al. reported a non-significant reduction in the risk of pre-eclampsia in women with GDM taking metformin, but a significantly reduced risk of gestational hypertension; this is in line with our findings 43 . In contrast to the findings of the Cochrane review, Alqudah et al. found a significant association between metformin use and reduced risk of pre-eclampsia when compared with insulin use 44 ; however, studies involving patients with type 2 diabetes were included. Compared with previous reviews, we provide the Bayesian estimates in the form of posterior probabilities. In general, metformin use was associated with a high probability of beneficial effect in the prevention of HDP. Bayesian analysis allows the probabilistic interpretation of results and avoids the problems arising from null hypothesis testing (i.e. type I and II errors).
Obesity is a known risk factor for the development of pregnancy-induced hypertension and pre-eclampsia. Trials that investigated increasing physical activity and limiting gestational weight gain during pregnancy have demonstrated a lower incidence of hypertensive disorders of pregnancy 45, 46 . The preventive effects of physical activity could be due to an improvement in cardiovascular function and/or reduced gestational weight gain. Of note, metformin has been reported to have beneficial effects in those at-risk women 42, [47] [48] [49] . Improved cardiovascular function and reduced gestational weight gain, in addition to its known stabilization of vasoactive mediators 11 , could be the underlying mechanisms of the beneficial effects of metformin. Weight gain is one of the factors that could contribute to the clinical heterogeneity that we observed in this analysis. Future studies on this topic should carefully investigate this factor and its association with late-onset pre-eclampsia in addition to metformin use.
Conclusions
Metformin is associated with a high probability of preventing any HPD when compared with other treatments. The small number of included studies and their clinical heterogeneity preclude the generalization of these results to broader populations. Therefore, randomized trials on metformin use for the prevention of pre-eclampsia are urgently needed.
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article: Appendix S1 Search strategies for randomized controlled trials on metformin use, reporting incidence of pre-eclampsia or pregnancy-induced hypertension. Figure S1 Forest plots of studies comparing metformin with insulin for prevention of pregnancy-induced hypertension, pre-eclampsia or any hypertensive disorder of pregnancy. Each study is represented by a line. Box represents point effect estimate of study. Midpoint of box represents point effect estimate, i.e. mean effect estimate for each study. Area of box represents weight given to study. Diamond represents overall estimate. Width of line shows CI of effect estimate of individual studies. Width of diamond represents CI for overall effect estimate. Heterogeneity (I 2 ) = diversity between studies.
Figure S2
Forest plots of studies comparing metformin with glyburide for prevention of pregnancy-induced hypertension, pre-eclampsia or any hypertensive disorder of pregnancy. Each study is represented by a line. Box represents point effect estimate of study. Midpoint of box represents point effect estimate, i.e. mean effect estimate for each study. Area of box represents weight given to study. Diamond represents overall estimate. Width of line shows CI of effect estimate of individual studies. Width of diamond represents CI for overall effect estimate. Heterogeneity (I 2 ) = diversity between studies.
Figure S3
Forest plots of studies comparing metformin with placebo for prevention of pregnancy-induced hypertension, pre-eclampsia or any hypertensive disorder of pregnancy. Each study is represented by a line. Box represents point effect estimate of study. Midpoint of box represents point effect estimate, i.e. mean effect estimate for each study. Area of box represents weight given to study. Diamond represents overall estimate. Width of line shows CI of effect estimate of individual studies. Width of diamond represents CI for overall effect estimate. Heterogeneity (I 2 ) = diversity between studies.
Figure S4
Forest plots of studies comparing metformin with other drugs or placebo for prevention of pregnancy-induced hypertension, pre-eclampsia or any hypertensive disorder of pregnancy. Each study is represented by a line. Box represents point effect estimate of study. Midpoint of box represents point effect estimate, i.e. mean effect estimate for each study. Area of box represents weight given to study. Diamond represents overall estimate. Width of line shows CI of effect estimate of individual studies. Width of diamond represents CI for overall effect estimate. Heterogeneity (I 2 ) = diversity between studies.
Table S1
Summary of findings of randomized controlled trials on metformin compared with other drugs or placebo, according to outcome La metformina para la prevención de los trastornos hipertensivos del embarazo en mujeres con diabetes gestacional u obesidad: revisión sistemática y metaanálisis de ensayos aleatorizados
RESUMEN
Objectivo Se ha informado que la metformina reduce el riesgo de preeclampsia. También se sabe que influye en el nivel de la tirosina quinasa 1 soluble similar a la fms, que está correlacionada significativamente con la edad gestacional al comienzo de la preeclampsia y su gravedad. El objetivo principal de esta revisión sistemática y del metaanálisis de los ensayos aleatorizados fue determinar si el uso de metformina está asociado con la incidencia de trastornos hipertensivos del embarazo (THE). Se realizaron búsquedas en MEDLINE (desde 1947 a septiembre de 2017), Scopus (desde 1970 a septiembre de 2017) y en la Cochrane Library (desde el inicio hasta septiembre de 2017) para encontrar citas bibliográficas relevantes en inglés. Sólo se incluyeron ensayos controlados aleatorizados sobre el uso de metformina que informaron sobre la prevalencia de la preeclampsia o la hipertensión inducida por el embarazo. Se excluyeron los estudios sobre poblaciones con una alta probabilidad de uso de metformina antes de la aleatorización (poblaciones con diabetes mellitus o síndrome de ovario poliquístico). Para los análisis de subgrupos se utilizaron modelos de efectos aleatorios mediante el método de Mantel-Haenszel. Se utilizó la metarregresión de efectos aleatorios bayesiana para resumir las pruebas.
Resultados En total, 3337 citas bibliográficas cumplieron los criterios de búsqueda. Después de evaluar 2536 resúmenes y realizar una revisión del texto completo de 52 estudios, se incluyeron 15 en la revisión. En las mujeres con diabetes gestacional, el uso de metformina se asoció con un menor riesgo de hipertensión inducida por el embarazo en comparación con la insulina (riesgo relativo (RR), 0,56; IC 95%: 0,37-0,85; I 2 =0%; 1260 mujeres) y un riesgo de preeclampsia no reducido significativamente (RR, 0,83; IC 95%: 0,60-1,14; I 2 =0%; 1724 mujeres). En las mujeres obesas, en comparación con el placebo, el uso de metformina se asoció con una reducción no significativa del riesgo de preeclampsia (RR, 0,74; IC 95%: 0,09-6,28; I 2 =86%; 840 mujeres). En las mujeres con diabetes gestacional, el uso de metformina se asoció también con una reducción no significativa del riesgo de cualquier THE (RR, 0,71; IC 95%: 0,41-1,25; I 2 =0%; 556 mujeres) en comparación con la glibenclamida. Cuando los estudios se combinaron mediante la metarregresión de efectos aleatorios bayesiana, con el tipo de tratamiento como covariable, las probabilidades posteriores de que la metformina tuviera un efecto beneficioso sobre la prevención de la preeclampsia, la hipertensión inducida por el embarazo y cualquier THE fueron del 92,7%, 92,8% y 99,2%, respectivamente, en comparación con cualquier otro tratamiento o placebo.
